Clinical experience with exenatide in a routine secondary care diabetes clinic.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 20022310.
- Also identified by DOI 10.1016/j.pcd.2009.11.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Exenatide use in type 2 diabetes is limited in routine clinical practice. We examined a cross-section of 90 patients. Mean weight and HBA(1c) were 114.9+/-20.6 kg, 10.3+/-2.1% at initiation; 108.0+/-15.3 kg (p<0.0001), 9.0+/-2.1% (p<0.001) at 3 months; 109.2+/-18.2 kg (p<0.0001), 9.5+/-2.3% (p=0.08) at 6 months. Exenatide appears effective in reducing HBA(1c) and weight.
Medical subject headings
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Peptides
- Venoms